

WILLIAM M. PATTERSON, M.D.

Birmingham Research Group, Inc.
2120 Lynngate Drive
Birmingham, AL 35216
Phone: (205) 823-0766
Fax: (205) 823-9410
Email: brg_wmp@bellsouth.net

EDUCATION:

1957-1960	Gadsden High School, Gadsden, AL
1960-1964	Self-employed professional gymnast and part-time student, University of Alabama Extension Center, Gadsden, AL
1964-1968	University of Alabama, Tuscaloosa, AL Major: Pre Med (Psychology): B.S. Degree
1968-1972	University of Alabama, School of Medicine, Birmingham, AL. M.D. Degree

GRADUATE EDUCATION:

1972-1975 Residency	Letterman Army Medical Center, Presidio of San Francisco, CA. Residency training in General Psychiatry including experience in inpatient milieu therapy for an array of diagnostic categories; large & small group psychotherapy; pharmacotherapy; electroconvulsive therapy, sensitivity group; outpatient clinic services; hypnotherapy, behavior therapy; sexual dysfunction therapy; biofeedback therapy; training seminars for ward personnel.
---------------------	---

ADDITIONAL TRAINING:

1973	UCLA, Short Course, Behavior Modification
1974	UCLA, Short Course, Sexual Dysfunction
	UCLA, Short Course, Biofeedback
1975	Current Trends in Military Psychiatry, Symposium on Sleep Disorders, San Francisco, CA

1976	Short Course, Behavior Modification Psychiatric Audit Team Seminar
1977	Short Course, Comparative Psychiatric Therapies
1978	Short Course, Short Term Dynamic Psychotherapy
1979	Short Course, AMEDD Forensic Psychiatry
1979	Short Course, Advances in Psychopharmacology for Psychiatrists

PROFESSIONAL EXPERIENCE:

1994 - Present	Psychiatric Consultant Association for Retarded Citizens Birmingham, AL
1992 - Present	Medical Director, Behavioral Health Systems Birmingham, AL
March, 1990-May, 1993	Director of Research; Director, Anxiety Disorders Program; and Chairman, Institutional Review Board, Hill Crest Hospital
May, 1989-Present	President, Birmingham Research Group, Inc.
September, 1988-Present	Private Practice, General Psychiatry, Birmingham, AL
September, 1988-March, 1990	Director, Anxiety Disorders Program, AMI Brookwood Medical Center
October, 1987-September, 1988	Vice Chairman and Director of Psychiatric Training, Department of Psychiatry, UAB
October, 1987-September, 1988	Professor, Department of Psychiatry, UAB
October, 1985-September, 1988	Director, Anxiety Disorders Program, UAB
October, 1983-September, 1988	Director, Adult Outpatient Psychiatry Services, UAB
January, 1983-September, 1988	Chief, Psychiatric Consultation Svc, BVAH
October, 1982-September, 1987	Associate Professor, Dept. of Psychiatry, UAB
April, 1982-September, 1988	Director, Psychiatry Residency Training Program, UAB

July, 1980-September, 1982	Assistant Professor, Dept. of Psychiatry, Liaison Consultation Service, University of Alabama in Birmingham
1979-June, 1980	Director, Psychosomatic Fellowship Program, Department of Psychiatry & Neurology, Eisenhower Army Medical Center
1976-June, 1980	Chief, Biofeedback Lab & Clinic, Regional Consultant, DDEAMC
1975-June, 1980	Chief, Psychiatry Outpatient Clinic, Dwight David Eisenhower Army Medical Center, Fort Gordon, GA
<u>OTHER ACTIVITIES:</u>	
1974-1975	Consultant to Mather Air Force Base Mental Hygiene Clinic, Sacramento, California
January, 1980	Examiner, American Board of Psychiatry & Neurology, Atlanta, GA
1980	Member, Association for Academic Psychiatry Task Force on Consultation Liaison Guidelines
1980-1988	Liaison Psychiatrist to UAB Pain Center
1982-1988	Member, Executive Committee, UAB Department of Psychiatry
1982-1984	Consultant, UAB/Cooper Green Sleep Disorders Center
1982-1984	Member, AADPRT Task Force on Resident Moonlighting
October, 1983	Symposium Coordinator: "Recent Advances: Management of Anxiety, Panic and Phobic Disorders", UAB Department of Psychiatry
January, 1984	Examiner, American Board of Psychiatry and Neurology, Houston, TX
1984-1988	Psychiatric Consultant, NIH Genetic Research Project

February, 1984	"Healthline" Volunteer Sponsor: Jefferson County Medical Society
April, 1985	Examiner, American Board of Psychiatry and Neurology, Atlanta, GA
1985-1988	Member, AADPRT Committee on Curriculum Development
1985-1988	Member, Search Committee for Discipline Chief in Psychiatry, University of Alabama College of Community Health Sciences
1985-1988	Member, Indigent Drug Program Formulary Committee, Alabama Department of Mental Health and Mental Retardation
1985-Present	Medical Advisor, Office of Hearings and Appeals, Social Security Administration
1985-1988	Consultant, UAB Sleep/Wake Disorders Center
October, 1985	Symposium Coordinator: "Anxiety, Panic & Phobic Disorders", UAB Department of Psychiatry
November, 1985	"Healthline" volunteer Sponsor: Jefferson County Medical Society
November, 1985-May, 1987	Chairman, Membership Committee of the Alabama Psychiatric Society (District Branch of the American Psychiatric Association)
November, 1985-May, 1987	Member, Continuing Education Committee, Alabama Psychiatric Society (District Branch of the American Psychiatric Association)
March, 1986	Symposium Coordinator: "Clinical Interface: Psychiatry and Cardiology-Current Perspectives", UAB Department of Psychiatry
January, 1987	Examiner, American Board of Psychiatry and Neurology, Houston, TX

1987-Present	Member, Membership Committee, Academy of Psychosomatic Medicine
1987-1989	President-Elect, The Birmingham Chapter of the Alabama Psychiatric Society (District Branch of the American Psychiatric Association)
1987-1989	Vice-President, the Alabama Psychiatric Society (District Branch of the American Psychiatric Association)
1987-1988	Acting President, the Alabama Psychiatric Society (District Branch of the American Psychiatric Association)
1987	Member, Multidisciplinary Task Force on the Liability of Mental Health Professionals in Alabama
October, 1987	Course Director: "Chronic Pain: A Clinical Update" - symposium Sponsor: the UAB Department of Psychiatry
December, 1987	Member, Advisory Committee, Anchor Developmental Center
1987-1988	Reviewer, American Journal of Medicine
1987-1988	Reviewer, Alabama Journal of Medical Sciences
1988	Member, Advisory Board, Nominating Committee, Friends of UAB Psychiatry
February, 1988	"Healthline" volunteer Sponsor: the Jefferson County Medical Society
September, 1988	"Anxiety and Panic Disorders" - presented to The Sharing Group, Birmingham, AL
1988-1993	Member, Investigational Review Board (Research Committee) Brookwood Medical Center; Member, Medical Education/Library Comm., Brookwood Medical Center
1989-1990	President, Alabama Psychiatric Society

1989-1990	President, Birmingham Chapter, Alabama Psychiatric Society
1990-1993	Pharmacy & Therapeutics Committee & Relocation Committee, Hill Crest Hospital
1992-1994	Chairman, Alabama Psychiatric Society Nominating and Fellowship Committee
1994 - Present	President, Society for Clinical Researchers in Pharmacology (SCRIP)
1995 - Present	President, Psychiatric Research Network
1995 - Present	Member, American Society of Clinical Psychopharmacology, Inc. (ASCP) Clinical Trials Committee and Chairman, Workgroup on Qualifications of Investigators
September, 1996 - Present	Member, American Society of Clinical Psychopharmacology, Inc. (ASCP) Membership Committee

PUBLICATIONS AND PAPERS:

Gallager, J. & Patterson, W: The Effect of Two Types of Associative Linkage and Position of Association Linkage on Recall of Sentences." *Psychon. Sci*, 21(2), 1970.

Patterson, W.M.: "Treatment of Raynauds Phenomenon With Temperature Biofeedback." *American Journal of Clinical Biofeedback*, 2:19-21, 1979.

Patterson, W.M.: "The Future Role of Psychiatry in Primary Care." Paper presented at the 134th Annual Meeting of the APA, New Orleans, May, 1981.

Patterson, W.M.; Hall, K: (Correspondence Section) "Use of I.V. Haloperidol." *Am. Family Physician*. 24(2), August, 1981.

Patterson, W.M.; Logan, W.E.; Vandewalle, M.D.: "PCP Psychosis in a General Hospital". *Mil. Med*. 147:311-312, April, 1982.

Patterson, W.M.: "Toxic/Therapeutic Ratio of the Benzodiazepines" (Letter to Ed.) *Clinical Psychiatry News*, May, 1982.

Patterson, W.M.: Comment & Consultation: "Drugs for Alcohol Withdrawal". *Consultant*, 22:17, December, 1982.

Patterson, W.M.; Dohn, H.; Bird, J.; Patterson, G.: "Evaluation of Suicidal Patients: The 'SAD PERSONS' Scale". *Psychosomatics* 24:343-349, 1983.

Patterson, W.M.: "Identity Crisis in Psychiatry" (Letter to Ed.) *M D* 27:12, 1983.

Patterson, W.M.: Comment & Consultation: "Tricyclics and Arrhythmias". *Consultant* 23:249, 1983.

Walter-Ryan, W.G.; Patterson, W.M.: "Treatment for Catatonic Symptoms with Intramuscular Lorazepam". *J. Clin Psychopharmacol* 5:123-124, 1985.

Shehi, M., Patterson, W.M.: "Treatment of Panic Attacks with Alprazolam and Propranolol". *Am. J. Psychiatry* 141:900-901, 1984.

Patterson, W.M.; Burch, E.A.: "Office Diagnosis and Management of Anxiety Disorders". CME Videotape #014. Produced by the UAB Office of Health Extension, Public Service and Research, 1984.

Patterson, W.M.; Shehi, M.; et.al. "Anxiety: Is Yours Normal?" Better Health, Vol. II, No. 3, March, 1985.

Patterson, W.M.: "Phobia: Our Worst Fears". *Birmingham Magazine*, April, 1985.

Shehi, M.; Patterson, W.M.: "Interactions of Benzodiazepines and Other Commonly Used Drugs". *IM - Internal Medicine for the Specialist*, 6:95-103, 1985.

Patterson, W.M.: "Results with the DST in Geriatric Patients" (Abstract). *Psychosomatics*, 26:469, 1985.

Earle, J.; Patterson, W.M.: "Chronic Pain, Neuroleptics and Tardive Dyskinesia: A Case Report". *Psychosomatics*, 27:291-293, 1985.

Patterson, W.M.: "Anxiety and Depression in the Cardiac Patient". *Audio Digest: Internal Medicine*. Vol. 31, No. 11, June 5, 1985.

Patterson, W.M.: "Higher Familial Incidence of Agoraphobia (Abstract)". *Psychosomatics* 26:691-692, 1985.

Patterson, W.M.: "Age at Onset in Anorexia not Prognostically Significant" (Abstract). *Psychosomatics* 27:232, 1985.

Patterson, W.M.; Eubanks, A.A.; Hermech, D.A.; et.al. "MMPI Profiles in Patients with Panic Disorder". Paper presented at the 32nd Annual Meeting, Academy of Psychosomatic Medicine, San Francisco, CA, November, 1985.

- Patterson, W.M.: "Agoraphobia Treatment" (Letter to Ed.) *Psychiatry* '86, April, 1986.
- Patterson, W.M.: "Clinical Update: Anxiety and Depression". *Ala. J. Med. Sci*, 23:402-407, 1986.
- Patterson, W.M.: Book Review - Textbook of Pain. Edited by Patrick D. Wall and Ronald Melzack. New York, Churchill Livingstone, 1984. 866 pages. *J. Clin. Psychiatry* 47:527, 1986.
- Patterson, W.M.: Abstract - "Current Thinking about MAOI's". *Psychosomatics* 27:675-676, 1986.
- Patterson, W.M., et.al: "MMPI Profiles in Patients with Panic Disorder". *Highland Highlights*, Vol. 10:19-23, 1986.
- Patterson, W.M.: "Use of anti-panic drugs during pregnancy", "Dear Doctor", *The Birmingham News*, January 1987.
- Patterson, W.M.: "Phobias: You Can Overcome Them". Better Health 4:2-4, 1987.
- Patterson, W.M.: "Triazolam Withdrawal". (Letter to Ed.) *J. Clin Psychiatry*, 51:369, 1988.
- Patterson, W.M.; Koplan, A.L.; Shehi, G.M.; Eubanks, A.A.: "The Use of Propranolol in the Treatment of Panic Disorder". Paper presented at the 35th Annual Meeting, Academy of Psychosomatic Medicine, New Orleans, November, 1988.
- Riesenberg, R.; Cohn, J.; Patterson, W.M.: "Etoperidone in the Treatment of Major Depression: A Placebo-controlled Clinical Trial". Paper presented at NCDEU, Key Biscayne, FL, May, 1989.
- Riesenberg, R.; Cohn, J.; Patterson, W.M.: "Etoperidone: Efficacy and Safety in Major Depression". Paper presented at the 142nd Annual Meeting of the APA, San Francisco, CA, May, 1989.
- Alhadeff, L.H.; Patterson, W.M.: "Treatment of PMS with Fluoxetine". Scientific paper presented at the Annual Meeting of the Academy of Psychosomatic Medicine, Phoenix, AZ, November, 1990.
- Patterson, W.M.: "Pain and depression: The use of psychotropic drugs". *Pain Digest*, 2:49-56, 1992.
- Carter, C.S.; Fawcett, J.; Herzman, M.; Papp, L.; Jones, W.; Patterson, W.M., et.al: "Adinazolam SR in Panic Disorder with Agoraphobia: A Fixed Dose Study of Efficacy and its Relationship to Drug Plasma Levels". (Submitted for publication, October, 1992).
- Patterson, W.M.: "Fluoxetine-Induced Sexual Dysfunction" (Letter to Ed.) *J. Clin. Psychiatry*, 54:71, February, 1993.
- Schweizer, Edward; Patterson, W.M.; Rickels, Karl; Rosenthal, Murray: "Double-Blind, Placebo-Controlled Study of a Once-a-Day, Sustained-Release Preparation of Alprazolam for the Treatment of Panic Disorder". *Am J Psychiatry*, 150:1210-1215, August, 1993.

Carter, Cameron S.; Fawcett, Jan; Hertzman, Marc; Papp, Laszlo A.; Jones, Wayne; Patterson, William M.; Swinson, Richard P.; Weise, Charles C.; Maddock, Richard J.; Sheridan, Angelita Q.; Liebowitz, Michael: "Adinazolam-SR in Panic Disorder with Agoraphobia: Relationship of Daily Dose to Efficacy". J. Clin. Psychiatry, Vol. 56 #5 pg 202-210, May, 1995.

Nemeroff, Charles B.; Ninan, Philip T.; Ballenger, James; Lydiard, R. Bruce; Feighner, John; Patterson, William M.; Greist, John H.: "Double-Blind Multicenter Comparison of Fluvoxamine Versus Sertraline in the Treatment of Depressed Outpatients". Depression, 3:163-169, 1995.

CERTIFICATION

1973	Diplomate of the National Board of Medical Examiners
1976	Diplomate of the American Board of Psychiatry and Neurology
1982	Certified Biofeedback Therapist, Biofeedback Certification Institute of America
1984	Certified Forensic Examiner, Alabama Department of Mental Health

LICENSES

1973	Alabama (#6433) California (inactive)
1978	Georgia Florida (exp. 12/83)

PROFESSIONAL ORGANIZATIONS:

1972-1975	National Association of Interns & Residents
1973	American Psychiatric Association
1975	American Medical Association
1978-1980	Association of Military Surgeons of the U.S.
1978	Academy of Psychosomatic Medicine
1979	American Psychosomatic Society
1981	Alabama Academy of Neurology & Psychiatry
1982	The Association for Applied Psychophysiology and Biofeedback
1982-1988	American Association Directors of Psychiatry Residency Training
1983-1988	Association for Academic Psychiatry
1986	American Pain Society
1986	Phobia Society of America
1988	Southern Medical Association
1989	American College of Psychiatrists
1993	American Society of Clinical Psychopharmacology, Inc.
1994	The Birmingham Academy of Medicine
1994	Southern Psychiatric Association
1994	Charter Member, Society for Clinical Researchers in Pharmacology (SCRIP)
1998-2001	Member, Board of Directors, Birmingham Academy of Medicine
1999	Life Member, #73992, National Registry of Who's Who

CLINICAL APPOINTMENTS:

1988-Present Clinical Professor of Psychiatry, UAB
 1977-1980 Clinical Associate Professor of Psychiatry, Medical College of Georgia

AWARDS:

1975-Present AMA & APA Physicians Recognition Award
 1977, 1979 The American Academy of Family Physicians, Teaching Award
 Presented by the Dept. of Family Practice, DDEAMC
 1980 Outstanding Faculty Teacher, Dept. Psychiatry, UAB
 1981 Outstanding Faculty Teacher, Dept. Psychiatry, UAB
 1983 Outstanding & Meritorious Service Award
 Office of the Mayor, Birmingham, AL
 1984 Fellow, American Psychiatric Association
 1988 Who's Who in the South and Southwest - 21st Edition
 1988 Fellow, Academy of Psychosomatic Medicine
 1989 Member, American College of Psychiatrists
 1995 National Alliance for the Mentally Ill - Exemplary Psychiatrist Award
 2003 Distinguished Fellow, American Psychiatric Association
 2004 Fellow, Southern Psychiatric Association
 2004 Distinguished Life Fellow, American Psychiatric Association

MILITARY SERVICE:

1972 Captain, United States Army Medical Corps
 1975 Major, United States Army Medical Corps
 1980 Lieutenant Colonel, United States Army Medical Corps

PERSONAL DATA:

DOB: 19 SEPT 41
 Place of Birth: Gadsden, Alabama
 Citizenship: United States

CIVIC ACTIVITIES

Deacon, Mountain Brook Presbyterian Church, Mountain Brook, AL
 Member, Camp-Smile-A-Mile, Children's Hospital, Birmingham
 Supporter, Learning Disabilities Association, Greater Birmingham Area Chapter
 Member, Lions Club International-Inverness Chapter

RESEARCH INTERESTS & EXPERIENCE:

Anxiety, Panic & Phobic Disorders
Chronic Pain
Depression
Liaison Psychiatry
Biofeedback
Schizophrenia

SPECIFIC AREAS OF EXPERTISE & INTEREST FOR TEACHING ACTIVITIES:

Pharmacotherapy
Liaison-Consultation/Psychosomatic Medicine
Biofeedback & Behavioral Therapy Techniques
The Psychotherapies

GRANT AWARDS:

- 1983 NIMH Psychiatry Comprehensive Institutional Training Grant
1984 NIMH Psychiatry Comprehensive Institutional Training Grant
1985 NIMH Psychiatry Comprehensive Institutional Training Grant

CLINICAL TRIALS:

- 1984 A Comparative Study of Alprazolam, Propranolol, Placebo and Combined Alprazolam-Propranolol in the Treatment of Panic Disorder. Protocol # 4417
Sponsor: The Upjohn Company
- 1986 Etoperidone: Safety and Efficacy vs Amitriptyline in Outpatients with Recurrent Depression.
Sponsor: McNeil Pharmaceutical
- 1987 Efficacy and Safety of Etoperidone in Outpatients with Major Depression.
Protocol # ERA 0341
Sponsor: McNeil Pharmaceutical
- 1988 A Multicenter Study Comparing Xanax S.R. and Xanax S.R. Placebo Tablets in the Treatment of Panic Disorder. Protocol # 4452
Sponsor: The Upjohn Company

- 1989 Etoperidone: Efficacy and Safety in Outpatients with Major Depression.
Protocol #ERA 0341N
Sponsor: McNeil Pharmaceutical
- 1989 Tramadol Hydrochloride: Long Term Safety in Patients with Chronic Non-malignant Pain.
Protocol # TKB
Sponsor: McNeil Pharmaceutical
- 1989 A Double-Blind Evaluation of the Safety and Efficacy of ZK 112-119, Alprazolam and Placebo in Outpatients with Generalized Anxiety Disorder. Protocol # B202
Sponsor: Sandoz Pharmaceuticals Corporation
- 1989 A Double-Blind Evaluation of the Safety and Efficacy of ZK 112-119, Alprazolam and Placebo in Outpatients with Panic Disorder. Protocol # C201
Sponsor: Sandoz Pharmaceuticals Corporation
- 1989 Tomoxetine/Desipramine/Placebo Trial in MDD. Protocol # B4Z-MC-HFAY
Sponsor: Eli Lilly and Company
- 1989 Collaborative Fixed-Dose Study of the Efficacy and Safety of Deracyn-SR Tablets in Panic Disorder with Agoraphobia. Protocol # M/2300/0046
Sponsor: The Upjohn Company
- 1990 A Triple-Blind, Placebo-Controlled Evaluation of Remoxipride in Prevention of Relapse in Schizophrenia. Protocol MK-843-003-00
Sponsor: Merck Sharp & Dohme Research Laboratories
- 1990 Double-Blind Parallel Study of Tolectin Tolmetin Sodium 1000 mg. Daily versus 1800 mg. Daily in the Treatment of Osteoarthritis. Protocol # TECO
Sponsor: R.W. Johnson Pharmaceutical Research Institute
- 1990 Double-Blind Parallel Study of Tolectin Tolmetin Sodium 1000 mg. Daily versus 1800 mg. Daily in the Treatment of Rheumatoid Arthritis. Protocol # TECO
Sponsor: R.W. Johnson Pharmaceutical Research Institute
- 1990 Double-Blind Placebo Controlled Study of the Efficacy and Safety of Misoprostol in the Prevention of NSAID-Induced Duodenal Ulcers.
Sponsor: G.D. Searle and Company
- 1990 Double-Blind Controlled Study of the Efficacy and Safety of Misoprostol in the Healing of the NSAID-Induced Gastric Ulcers. Protocol # S81-89-02-028
Sponsor: G.D. Searle and Company

- 1990 Double-Blind Comparative Study of the Efficacy and Safety of Misoprostol and Ranitidine in the Prevention of NSAID-Induced Gastric Ulcers and Upper GI Symptoms. Protocol # S81-88-02-006 Sponsor: G.D. Searle and Company
- 1991 Double-Blind Parallel Comparison of Sertraline, Imipramine and Placebo in Inpatients with Major Depression or Bipolar Disorder, Depressed. Protocol # 86-CE21-0239 Sponsor: Pfizer, Inc.
- 1991 Fixed Dose, Double-Blind Study Comparing the Efficacy and Safety of Xanax SR Tablets vs Placebo in the Treatment of Panic Disorder Using Once Daily Dosing. Protocol # M/2002/0003. Sponsor: The Upjohn Company/IBRD
- 1991 A Double-Blind Evaluation of Ketoprofen and Ibuprofen for Over-The-Counter Use. Protocol # 90-3 Sponsor: Miles, Inc.
- 1991 Flexible-Dose, Double-Blind, Study Comparing Efficacy and Safety of Deracyn SR Tablets vs Xanax CT in the Treatment of Geriatric Outpatients with Clinical Anxiety. Protocol #M/2300/0097.Sponsor: The Upjohn Company
- 1991 A Prospective Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Groups Comparison of the Efficacy and Safety of Abecarnil (7.5 -17.5 mg) and Alprazolam (1.5 - 3.5 mg) in Outpatients with Generalized Anxiety Disorder. Protocol # B351 Sponsor: Sandoz Pharmaceutical Corporation
- 1991 Double-Blind, Placebo Controlled, Comparative Study of the Efficacy and Safety of Three Dosage Regimens of Misoprostol in the Prevention of NSAID-Induced Gastric Ulcers. Protocol # S81-89-02-053 Sponsor: G.D. Searle and Company
- 1992 Zatosetron Maleate in Patients with Generalized Anxiety Disorder - F2V-MC-HKAA, IND 37715. Protocol # F2V-MC-HKAA. Sponsor: Eli Lilly and Company
- 1992 A Prospective, Randomized, Double-Blind, Multicenter, Parallel-Groups Comparison of the Efficacy and Safety of Abecarnil (7.5 - 17.5 MG) and Placebo in Outpatients with Generalized Anxiety Disorders. Protocol # B356 Sponsor: Sandoz Pharmaceutical Corporation
- 1992 A Prospective, Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel-Groups Comparison of the Safety and Efficacy of Abecarnil (3.0 - 9.0 MG) and Lorazepam (1.5 - 4.5 MG) in Elderly Outpatients with Anxiety Symptoms. Protocol # B371 Sponsor: Sandoz Pharmaceutical Corporation

- 1992 A Multicenter, Double-Blind, Placebo-Controlled Comparison of Low and High Dosage Regimens of ICI 204,636 in the Treatment of Hospitalized Patients with Acute Exacerbation of Subchronic or Chronic Schizophrenia. Protocol # 5077IL/0001
Sponsor: ICI Pharmaceuticals Group
- 1992 A Phase II, Exploratory Study to Evaluate the Efficacy and Safety of CP-93,393 in Outpatients with Generalized Anxiety Disorder During a Nine- to Ten-Week Treatment Period. Protocol #129-101-506. Sponsor: Pfizer.
- 1992 Fosfomycin Tromethamine Versus Ciprofloxacin in Uncomplicated Urinary Tract Infections. Protocol # MON- US-01. Sponsor: Forest Laboratories, Inc.
- 1992 L-365,260 vs Placebo in Panic Disorder. Protocol # L- 365,260. Sponsor: Merck, Sharp & Dohme Research
- 1992 A Double-Blind, Randomized Trial of Paroxetine versus Placebo in Patients with Depression Accompanied by Anxiety.
Sponsor: SmithKline Beecham Pharmaceuticals
- 1992 Long-Term Safety Study with Alprostadil Sterile Powder (PGE₁) (Alprostadil S. Po.) in Patients with Erectile Dysfunction. Protocol # M/5650/0070
Sponsor: The Upjohn Company
- 1992 Amesergide (LY237733) vs Placebo in the Treatment of Patients with Psychogenic Impotence.
Protocol # F2P-MC-LCAE
Sponsor: Eli Lilly and Company
- 1992 Flexible-Dose, Double-Blind Study Comparing Efficacy and Safety of Deracyn SR vs Xanax Compressed Tablets in the Treatment of Panic Disorder with Agoraphobia and Associated Depressive Symptoms. Protocol # M/2300/0099
Sponsor: The Upjohn Company/IBRD
- 1992 A Phase II, 8 - Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-102 in Outpatient's with Generalized Anxiety Disorder. Protocol # 129-102-506
Sponsor: Pfizer, Inc.
- 1992 Fluvoxamine versus Placebo in the Treatment of Panic Disorder: A Fixed-Dose, Double-Blind Study Comparing Efficacy and Safety. Protocol # M/2315/0002
Sponsor: The Upjohn Company/IBRD

- 1993 A Phase II, 6 - Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-103 in Outpatient's with Major Depressive Disorder. Protocol # 129-103-506
Sponsor: Pfizer, Inc.
- 1993 A Double-Blind, Fixed-Dose, Multicenter Study Comparing DN-2327 (2, 4, & 8 mg/day) with Placebo in Generalized Anxiety Disorder. Protocol # M-92,826
Sponsor: G.H. Besselaar Assoc.
- 1993 A Double-Blind Comparison of Tansospirone GITS and Placebo in the Treatment of Outpatients with Major Depression. Protocol # 93CE30-0609
Sponsor: Pfizer, Inc.
- 1993 An Open-Label, Long-Term Safety Study of DN-2327 in the Treatment of Patients with Generalized Anxiety Disorder. Protocol # M-93,007
Sponsor: G.H. Besselaar Associates.
- 1993 A Multi-Center, Double Blind, Randomized Trial Comparing the Effects of Nefazodone to Sertraline on Sexual Dysfunction in Patients with Previously Demonstrated Sexual Dysfunction with Sertraline During Treatment for Major Depressive Disorder. Protocol # CN-105
Sponsor: Bristol-Myers Squibb Company.
- 1993 A Double-Blind Trial Comparing Nefazodone to Fluoxetine in Patients with Activation Side Effects Previously Demonstrated During Treatment with Fluoxetine for Major Depressive Disorder. Protocol CN-103
Sponsor: Bristol-Myers Squibb Company.
- 1993 A Multicenter, Double-Blind, Randomized, Controlled, Multiple Fixed-Dose and Dose Regimen Comparison of Seroquel (ICI 204,636) and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia. Protocol # 5077IL/0015:0017
Sponsor: Zeneca Pharmaceuticals Group.
- 1993 A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Multiple Fixed Dose Comparison of Seroquel (ICI 204,636) and Haloperidol in the Treatment of Hospitalized Subjects with Acute Exacerbation of Chronic or Subchronic Schizophrenia. Protocol # 5077IL/0013:0025
Sponsor: Zeneca Pharmaceuticals Group.
- 1993 Safety Surveillance Study for Wellbutrin Sustained Release. Protocol # 208
Sponsor: International Clinical Research Corporation Burroughs Wellcome.

- 1993 A Double Blind Placebo-Controlled Dose Escalation Study of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder. Protocol # S3A-322
Sponsor: Glaxo Research Institute
- 1993 Fixed-Dose, Double-Blind Pilot Study in Panic Disorder Comparing the Effects of Routine Clinical Taper and Taper by Progressive Placebo Substitution in Panic Patients Responding to Treatment with Deracyn Tablets. Protocol # M/2300/0101
Sponsor: The Upjohn Company
- 1993 Multi-Center, 36 Week, Double-Blind, Parallel Group Safety, Tolerance and Efficacy Comparison of Placebo and Mentane (225 mg/d, 300 mg/d and 375 mg/d) in Outpatients with Alzheimer's Disease. Protocol # HP029-303
Sponsor: Hoechst-Roussel Pharmaceuticals, Inc./Kendle Research Associates
- 1993 A Double-Blind, Placebo-Controlled Study of Sumatriptan Suppositories in the Acute Treatment of a Single Migraine Attack. Protocol # S2B-351
Sponsor: Glaxo Research Institute
- 1993 Fluvoxamine in the Treatment of Depression: A Double-Blind, Multicenter, Comparison with Sertraline in Outpatients. Protocol # 114.8.05
Sponsor: Solvay Pharmaceuticals
- 1994 Safety and Efficacy of Depakote in the Prevention of Mania in Patients with Bipolar Disorder. Protocol # M-92,822 Sponsor: Abbott Laboratories
- 1994 A Phase II, Six Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-1 in Outpatients with Generalized Anxiety Disorder. Protocol # 129-105-506 Sponsor: Pfizer, Inc.
- 1994 Forty Week, Double-Blind Study Evaluating the Safety and Efficacy of Two Dose Regimens of Oral Ziprasidone (CP-88,059-1 (80-120 mg, QD, and 40-80 mg, BID) and Haloperidol (5-20 mg, Daily) in the Maintenance Treatment of Schizophrenia or Schizoaffective Disorder. Protocol # 128-108-578 Sponsor: Pfizer, Inc.
- 1994 Klonopin Dose Titration Study. Protocol # NZ14275B
Sponsor: Hoffmann LaRoche Research
- 1994 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Headache Pain Relief with Sumatriptan Nasal Spray (5 mg, 10 mg, and 20 mg) Across Three Migraine Attacks. Protocol # S2B-342
Sponsor: Glaxo Research

- 1994 Flesinoxan in the Treatment of Generalized Anxiety Disorder: A Multicenter, Double-Blind, Parallel, Placebo-Controlled Comparison with Diazepam in Outpatients. Protocol # 128.2.03
Sponsor: Solvay Pharmaceuticals
- 1994 An Exploratory Study of the Effect of Intracavernosal Alprostadil in Patients Suffering From Premature Ejaculation. Protocol # M/5650/0001
Sponsor: The Upjohn Company
- 1994 Phase III, Six Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Two Fixed Doses of Oral Ziprasidone (CP-88,059-1 (40 mg, BID and 80 mg, BID) in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder. Protocol # 128-114-677
Sponsor: Pfizer, Inc.
- 1994 A 52-Week, Open Extension Study Evaluating the Safety and Outcome of 40-80 mg, BID of Oral Ziprasidone (CP-88,059-1) Daily in the Treatment of Subjects Who Have Participated in Previous Ziprasidone (CP-88,059-1) Clinical Trials. Protocol # 128-116B-677.
Sponsor: Pfizer, Inc.
- 1994 A Double-Blind, Placebo-Controlled Dose-Escalation Study of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder. Protocol # S3A-323.
Sponsor: Glaxo Research
- 1994 Double-Blind Comparison of Sertraline and Placebo in Outpatients with Post-traumatic Stress Disorder. Protocol # 93-CE21-0640 Sponsor: Pfizer, Inc.
- 1994 A Phase II, Eight Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-1 in Outpatients with Major Depressive Disorder. Protocol # 129-106-506 Sponsor: Pfizer, Inc.
- 1994 A Randomized Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Tolerability in Patients Suffering From Dementia of the Probable Alzheimer's Type. Protocol # 202026/005
Sponsor: SmithKline Beecham Pharmaceuticals
- 1995 Fluoxetine/Placebo in Panic Disorder. Protocol # B1Y-MC-HCHG
Sponsor: Eli Lilly and Company
- 1995 A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK-462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache. Protocol 025-00 Sponsor: Merck & Co., Inc.
- 1995 An Open Label Administration of SB 202026 in Patients Suffering from Dementia of the Alzheimer's Type. Protocol 202026/007 Sponsor: SmithKline Beecham Pharmaceuticals

- 1995 Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of Venlafaxine-Extended Release Capsules in Outpatients with Generalized Anxiety Disorder. Protocol 600-B-210-US Sponsor: Wyeth-Ayerst Research
- 1995 A Comparative Cost-Effectiveness Study of Depakote and Usual Care Versus Lithium and Usual Care in the Treatment of Bipolar Disorder. Protocol M93-111 Sponsor: Abbott Laboratories
- 1995 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 25 mg, 50 mg and 100 mg Oral Sumatriptan in Adolescent Migraine Subjects. Protocol SUMA2002 Sponsor: Glaxo Research Institute
- 1995 A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Four Doses of Oral Naratriptan in the Acute Treatment of a Single Migraine Attack. Protocol S2WA3001 Sponsor: Glaxo Research Institute/IBRD-ROSTRUM Global
- 1995 A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Oral Naratriptan in the Acute Treatment of Four Migraine Attacks. Protocol S2WA3003 Sponsor: Glaxo Research Institute/IBRD-ROSTRUM Global
- 1995 Safety and Efficacy of Risperidone 8 mg QD and 4 mg QD Compared to Placebo in the Treatment of Schizophrenia. Protocol RIS-USA-72 Sponsor: Janssen Pharmaceutica, Inc.
- 1995 A Fifty-Two Week, Double-Blind Extension Study Evaluating the Safety and Efficacy of Two Dose Regimens of Oral Ziprasidone (CP-88,059-1) (80-120 mg, QD and 40-80 mg, BID) and Haloperidol (5-20 mg daily) in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder Who Have Successfully Completed Protocol 128-108. Protocol 128-108E-578 Sponsor: Pfizer, Inc.
- 1995 Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Butorphanol Tartrate Nasal Spray Versus Acetaminophen and Codeine Phosphate Capsules Versus Placebo in Patients with Acute Migraine Headache Pain. Protocol CN102-020 Sponsor: Bristol Myers Squibb/Corning PACT
- 1995 Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Butorphanol Tartrate Nasal Spray Versus Acetaminophen and Codeine Phosphate Capsules Versus Placebo in Patients with Acute Migraine Headache Pain. Protocol CN102-021 Sponsor: Bristol Myers Squibb/Corning PACT

- 1995 A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Tolerability of Oral Naratriptan in an Adolescent Migraine Population.
Protocol S2WA-3012 Sponsor: Glaxo Wellcome, Inc.
- 1996 A Ten Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in Outpatients with Major Depressive Disorder.
Protocol 129-107
Sponsor: Pfizer, Inc./Quintiles
- 1996 A Ten Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in Outpatients with Generalized Anxiety Disorder.
Protocol 129-108
Sponsor: Pfizer, Inc./Quintiles
- 1996 Six-Month, Double-Blind, Placebo-Controlled, Parallel Group Comparison of Venlafaxine Extended Release Capsules and Placebo in Outpatients with Generalized Anxiety Disorder.
Protocol 0600B2-218-US
Sponsor: Wyeth-Ayerst Research
- 1996 A Placebo-Controlled, Double-Blind, Flexible Dose Study of Sertraline in the Treatment of Post-Traumatic Stress Disorder
Protocol 96CE21-0682
Sponsor: Pfizer, Inc.
- 1996 Double-Blind, Placebo-Controlled Study of Venlafaxine-ER and Venlafaxine-OROS in Outpatients with Major Depression
Protocol 0600C1-217-US
Sponsor: Wyeth-Ayerst Research
- 1996 Fluoxetine Plus Pindolol Versus Fluoxetine Plus Placebo in the Treatment of Major Depression Protocol B1Y-MC-HZAA Sponsor: Eli Lilly
- 1996 A 24-Week Open Label Extension Study of Sertraline in Outpatients with Post-Traumatic Stress Disorder Protocol 95CE21-0672 Sponsor: Pfizer, Inc.
- 1996 The Efficacy and Safety of Alniditan (1.4 or 1.8 mg SC) Vs. Sumatriptan (6 mg SC) in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Trial. Protocol ALN-INT-16 Sponsor: Janssen Research
- 1996 A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan Tablet (25 or 50 mg) in the Acute Treatment of Migraine
Protocol SUMA4014 Sponsor: Glaxo Wellcome

- 1996 A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects with Acute Migraine
Protocol 160-102 Sponsor: Pfizer, Inc.
- 1996 A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of WELLBUTRIN (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression
Protocol AK1A4001 Sponsor: Glaxo Wellcome, Inc.
- 1996 A Multicenter, Randomized, Open-Label Comparative Study of the Safety, Tolerantion, and Efficacy of Oral Eletriptan for Long Term Treatment of Subjects with Acute Migraine
Protocol 160-108 Sponsor: Pfizer, Inc.
- 1996 A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome. Protocol 96CE21-0680 Sponsor: Pfizer, Inc.
- 1996 A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder
Protocol 29060/495 Sponsor: SmithKline Beecham
- 1996 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Alniditan (0.4, 0.8 or 1.4 mg) Given Subcutaneously in the Acute Treatment of Migraine
Protocol ALN-INT-17 Sponsor: Janssen Research
- 1996 A Double-Blind Continuation Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder. Protocol 96CE21-0703 Sponsor: Pfizer, Inc.
- 1997 A Double-Blind Trial of Three Fixed Doses of Nefazodone and Placebo in the Treatment of Patients with Panic Disorder. Protocol CN104-149 Sponsor: Bristol-Myers Squibb
- 1997 A Double-Blind, Randomized, Trial of Three Fixed Doses of Transdermal Buspirone Compared to Placebo in the Treatment of Anxious Outpatients. Protocol CN101-094
Sponsor: Bristol-Myers Squibb
- 1997 A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Oral Eletriptan in Adolescent Subjects Aged 12 to 17 Years with Acute Migraine. Protocol 160-105 Sponsor: Pfizer, Inc.
- 1997 A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR46349B in Outpatients with Major Depression. Protocol DRI2623 Sponsor: Sanofi

- 1997 A Multicenter, Randomized, Open-Label Comparative Study of the Safety, Toleration, and Efficacy of Oral Eletriptan for Long Term Treatment of Subjects with Acute Migraine Protocol 160-108 Sponsor: Pfizer, Inc.
- 1997 A Randomized, Double-Blind, Placebo Substitution Trial of the Efficacy of Nefazodone in the Long Term Continuation Treatment of Patients with Panic Disorder Protocol CN104-150 Sponsor: Bristol-Myers Squibb
- 1997 A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Three Dose Levels (5 mg, 10 mg, and 20 mg) of Sumatriptan Nasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs (12 – 17 years of age) Protocol Suma3005 Sponsor: Glaxo Wellcome
- 1997 An Open-Label Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Sumatriptan Nasal Spray in the Acute Treatment of Multiple Migraine Attacks in Adolescent Migraineurs (12 – 17 years of age) Protocol Suma3006 Sponsor: Glaxo Wellcome
- 1997 A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Tolerability and Efficacy of Three Fixed Doses of Fluvoxamine Versus Placebo in Outpatients with Major Depressive Disorder Protocol S1143102 Sponsor: Solvay Pharmaceuticals, Inc.
- 1997 A Double-Blind, Multicenter, Dose-Finding Acute and Extension Study of MK-0869 (L-754,030) vs. Fluoxetine and Placebo in the Treatment of Outpatients with Major Depressive Disorder Protocol 020 Sponsor: Merck & Co., Inc.
- 1997 Two-Period Crossover Comparison of Rizatriptan (5 mg p.o. and 10 mg p.o.) to Sumatriptan (25 mg p.o. and 50 mg p.o.) in the Acute Treatment of Migraine Protocol 052-02 Sponsor: Merck & Co.
- 1998 An International, Multicenter Trial of Two Dose Ranges of Nefazodone and Placebo in the Treatment of Outpatients with Posttraumatic Stress Disorder Protocol CN104-159 Sponsor: Bristol-Myers Squibb
- 1998 A Six-Week, Double-Blind, Placebo- and Fluoxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder. Protocol 165-112-5048 Sponsor: Pfizer, Inc.
- 1998 Almotriptan: A Long-Term Open Label Safety Study of Almotriptan 12.5 mg Orally in Migraine Patients. Protocol M/3275/0011 Sponsor: Pharmacia & Upjohn

- 1998 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 7-Week Evaluation of the Efficacy and Safety of Lamotrigine in Treatment of a Major Depressive Episode in Unipolar Depressed Patients
Protocol SCA20025 Sponsor: Glaxo Wellcome
- 1999 A Study of Low-Dose Flesinoxan in Patients with Generalized Anxiety Disorder (GAD; DSM-IV); A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety
Protocol H.128.5055 Sponsor: Solvay Pharmaceuticals
- 1999 Oral Almotriptan vs Oral Sumatriptan in a Double-Blind, Randomized, Parallel Group Study of Cost-Effectiveness and Quality of Life in Migraine
Protocol M/3275/0008 Sponsor: Pharmacia & Upjohn
- 1999 Duloxetine Versus Placebo in the Treatment of Major Depression
Protocol F1J-MC-HMAQ Sponsor: Eli Lilly and Company
- 1999 Flexible Dose Comparison of the Safety and Efficacy of LU 26-054, Citalopram, and Placebo in the Treatment of Major Depressive Disorder
Protocol SCT-MD-02 Sponsor: Forest Laboratories, Inc.
- 1999 Flexible Dose Comparison of the Safety and Efficacy of LU 26-054, Citalopram, and Placebo in the Treatment of Panic Disorder
Protocol SCT-MD-04 Sponsor: Forest Laboratories, Inc.
- 1999 A Twelve-Week, Randomized, Double-Blind, Placebo Controlled, Flexible Dose Study of Fluvoxamine CR in the Treatment of Generalized Social Anxiety Disorder
Protocol S1143107 Sponsor: Solvay Pharmaceuticals, Inc.
- 1999 Placebo-Controlled Evaluation of the Safety and Efficacy of LU 26-054 in the Prevention of Depression Relapse Protocol SCT-MD-03 Sponsor: Forest Laboratories
- 1999 A Placebo-Controlled Study of Pregabalin in Patients with Social Phobia
Protocol 1008-080-113 Sponsor: Parke-Davis
- 1999 A Placebo-Controlled Study of Pregabalin and Alprazolam in Patients with Generalized Anxiety Disorder. Protocol 1008-083 Sponsor: Parke-Davis
- 1999 A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine ER in Adult Outpatients with Generalized Social Anxiety Disorder
Protocol 0600B4-387-US Sponsor: Wyeth-Ayerst Research

- 1999 A Randomized, Open-Label, Two-Period Crossover Study Comparing Preference for Rizatriptan MLT 10 mg or Sumatriptan 50 mg Tablet for the Acute Treatment of Migraine Protocol MAX 478 Sponsor: Merck & Co.
- 2000 A Six-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of CP-448,187 (0.5, 3 and 10 mg) and Fluoxetine in Subjects with Major Depressive Disorder Protocol A2721002 Sponsor:: Pfizer, Inc.
- 2000 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel Group Comparative Study of the Efficacy and Safety of Oral Eletriptan (40 mg) and Sumatriptan (100 mg) Given for the Acute Treatment of Migraine. Protocol A1601048 Sponsor: Pfizer/Ingenix
- 2000 A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Study to Evaluate the Efficacy and Tolerability of Sertraline in Subjects Diagnosed with DSM-IV Generalized Anxiety Disorder. Protocol GAD-0040 Sponsor: The Clinical Innovation Group/Medical University of South Carolina
- 2000 A Randomized, Open-Label, Parallel Groups, Outpatient Study to Examine the Long-Term Safety and Tolerability of Rizatriptan 5 mg P.O. for the Acute Treatment of Migraine in Adolescents. Protocol 061-00 Sponsor: Merck & Co.
- 2000 An 8-Week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Study of Pagoclone in Patients with Panic Disorder Protocol 1043-009-030 Sponsor: Parke-Davis
- 2000 A 10-Week, Randomized, Double-Blind, Placebo-Controlled Study of Paroxetine and Pregabalin in Patients with Social Phobia Protocol 1008-153-208 Sponsor: Parke-Davis
- 2000 A Double-Blind, Placebo-Controlled Comparative Efficacy Study of Venlafaxine ER and Sertraline in Producing Remission in Outpatients with Major Depressive Disorder Protocol 0600B1-402-US Sponsor: Wyeth-Ayerst Research
- 2000 A Phase IIB, Six-Week, Double-Blind, Placebo- and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder. Protocol A1651002 Sponsor: Pfizer, Inc.
- 2000 A Seven-Week, Double-Blind, Extension of Protocol A1651002: A Phase IIB, Six-Week, Double-Blind, Placebo- and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder Protocol A1651007 Sponsor: Pfizer, Inc.

- 2000 Evaluation of the Safety and Efficacy of LU 26-054 in the Prevention of Depression Recurrence. Protocol SCT-MD-11 Sponsor: Forest Laboratories
- 2000 Fixed Dose Continuation Study of Escitalopram in the Treatment of Depressed Nonresponders. Protocol SCT-MD-08 Sponsor: Forest Laboratories
- 2000 A Randomized, Double-Blind, Alprazolam- and Placebo-Controlled Study of the Efficacy and Safety of CP-615,003 in Outpatients with Generalized Anxiety Disorder Protocol A3381003 Sponsor: Pfizer, Inc.
- 2001 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Protocol TOPMAT-MIGR-001 Sponsor: R.W. Johnson Pharmaceutical
- 2001 A 6-Week, Double-Blind, Randomized, Multicenter, Fixed-Dose Placebo-Controlled Study of Pagoclone Dosed Once a Day in Patients with Generalized Anxiety Disorder Protocol 1043-033 Sponsor: Pfizer, Inc.
- 2001 A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine Extended-Release Capsules in Adult Outpatients with Panic Disorder Protocol 0600B5-353-US Sponsor: Wyeth-Ayerst Research
- 2002 Double-Blind, Multicenter, Placebo and Active Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients with Major Depression Protocol 061 Sponsor: Merck Research Laboratories
- 2002 A Double-Blind, Placebo-Controlled Multicenter Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder. Protocol 068 Sponsor: Merck Research Laboratories
- 2002 Ro 67-5930 in Major Depressive Disorder: A Placebo- and Paroxetine-Controlled Study of Efficacy and Safety Protocol BN16430C Sponsor: Roche Pharmaceuticals
- 2002 Deramciclone 30 mg and 60 mg once daily versus placebo in generalized anxiety disorder. A randomized double-blind placebo- and buspirone-controlled fixed-dose parallel-group multicenter study of 10 weeks (including a 2-week single-blind placebo period). Protocol 3013025/DERA-5334-025 Sponsor: Pharmacia Corp.
- 2003 A Multicenter, Double-Blind, Randomized, Placebo Controlled Study of Eletriptan (20 and 40 mg) Versus Placebo in Early Treatment of Migraine Protocol A1601080 Sponsor: Pfizer, Inc.

- 2003 A Four-Week Double-Blind, Placebo and Active Controlled, Dose-Ranging Study of SL 65.1498-00, 3 doses (5, 15, 50 mg per day) and Lorazepam (3 mg/day) in Out-patients with Generalized Anxiety Disorder (GAD). Protocol DRI4390
Sponsor: Sanofi-Synthelabo Research
- 2003 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Three Fixed Doses (50 mg, 100 mg, or 200 mg) of DVS-233 SR in Adult Outpatients with Major Depressive Disorder.
Protocol 3151A1-306-US Sponsor: Wyeth Pharmaceuticals, Inc.
- 2003 A 10-month Open-Label Evaluation of the Long-term Safety of DVS-233 SR in Outpatients with Major Depressive Disorder. Protocol 3151A1-303-WW
Sponsor: Wyeth Pharmaceuticals, Inc.
- 2003 A Double-Blind, Multicenter, Randomized, Placebo-Controlled Efficacy and Safety Study of ORG 33062 ER in Subjects with Major Depressive Disorder. Protocol FKGBE008
Sponsor: Faber-Kramer Pharmaceuticals, Inc.
- 2004 A 10 week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL (up to 16 mg/day) in the Treatment of Adults with Generalized Anxiety Disorder. Protocol 6671/3031/AX/US
Sponsor: Cephalon, Inc.
- 2004 A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild. Protocol #065-00
Sponsor: Merck & Co., Inc.
- 2004 A 6-Month Open-Label Evaluation of the Long-Term Safety of DVS-233SR in Elderly Outpatients. Protocol No. 3151A1-307-US Sponsor: Wyeth Research
- 2004 A Randomized, Double-Blind, Placebo- and Active Comparator Controlled, Parallel-Group, Safety and Efficacy Study of OROS Alprazolam in Adults with Generalized Anxiety Disorder (GAD). Protocol 04-001-00 Sponsor: Jazz Pharmaceuticals
- 2005 A Long-Term, Open-Label, Safety and Efficacy Study of OROS® Alprazolam in Adults with Generalized Anxiety Disorder (GAD) Protocol 04-003-00
Sponsor: Jazz Pharmaceuticals
- 2005 A 12-month, open-label flexible-dosage study to evaluate the safety and efficacy of GABITRIL® treatment (up to 16mg/day) in adults with generalized anxiety disorder. Protocol 6671/3033/AX/US Sponsor: Cephalon, Inc.

- 2005 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients with Bipolar Disorder. Protocol 3168A2-304-US Sponsor: Wyeth Pharmaceuticals
- 2005 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients with Bipolar Disorder. Protocol 3168A2-307-WW Sponsor: Wyeth Pharmaceuticals
- 2005 An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients with Major Depressive Disorder (MDD). Protocol EFC 5041 Sponsor: Sanofi-Aventis, Inc.
- 2006 A multicenter, randomized, 30- to 52-week, double-blind, placebo- controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in the prevention of relapse or recurrence of depressive symptoms in outpatients with major depressive disorder who maintained clinical stability after an initial response to open-label treatment with saredutant 100 mg once daily. Protocol EFC 5576 Sponsor: Sanofi-Aventis, Inc.
- 2006 A Multi-centre, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-label Stabilization Period. Protocol D1448C00005 Sponsor: Astra Zeneca Pharmaceuticals
- 2006 A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Social Anxiety Disorder Protocol AV608-105 Sponsor: Avera Pharmaceuticals
- 2006 A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia Protocol 81-0045 Sponsor: Depomed, Inc.
- 2006 Patient Outcomes With Education, Drug Therapy, and Support (POETS) – A Multicenter, Open Label, Randomized, Study to Evaluate Depressed Patients Treated with Venlafaxine Extended-Release Vs. Venlafaxine Extended-Release Plus Dialogues Time to Talk Program in a Primary Care Setting Protocol 0600B1-416-US Sponsor: Wyeth Pharmaceuticals

- 2007 A Multi-centre, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-Therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY)
Protocol D1448C00014 Sponsor: Astra Zeneca
- 2007 A Multi-Centre, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Treatment of Elderly Patients with Generalized Anxiety Disorder (CHROMIUM STUDY)
Protocol D1448C00015 Sponsor: Astra Zeneca
- 2007 A multi-center, double-blind, parallel group, fixed dose, 4-arm, placebo and paroxetine controlled 8-week efficacy study of 2 oral doses of SR58611A (175 mg or 350 mg, b.i.d.) in adult population with Major Depressive Disorder
Protocol EFC 6607 Sponsor: Sanofi-Aventis
- 2007 A Randomized, Double-Blind, Two-Arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder
Protocol 04ACL3-001 Sponsor: Labopharm, Inc.
- 2007 An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorder
Protocol EFC 10290 Sponsor: Sanofi-Aventis
- 2007 A multi-center, double-blind, parallel group, fixed dose, 4-arm, placebo and paroxetine controlled 8-week efficacy study of 2 oral doses of SR58611A (175 mg or 350 mg, b.i.d.) in adult population with Major Depressive Disorder
Protocol C10953/2032/DP/US Sponsor: Cephalon, Inc.
- 2007 Efficacy and Safety of 2mg/day of MI00907 on Sleep Maintenance Insomnia with a sub-study of the effect of MI 00907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study.
Protocol LTE6672 Sponsor: Sanofi-Aventis
- 2008 A Randomized, Double-Blind, Parallel-group, Placebo-controlled, Fixed Dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults with Major Depressive Disorder
Protocol Lu AA21004_303 Sponsor: Takeda Global Research

- 2008 A Randomized, Double-Blind, Parallel-group, Placebo-controlled, Fixed Dose Study Comparing the Efficacy and Safety of two doses of LuA21004 in Acute Treatment of Adults with Generalized Anxiety Disorder
Protocol Lu AA21004_309 Sponsor: Takeda Global Research
- 2008 A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia
Protocol 81-0062 Sponsor: Depomed, Inc.
- 2008 A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients with Major Depressive Disorder Who Have Responded Inadequately to Prior ADT
Protocol: ADAPT Sponsor: Massachusetts General Hospital
- 2008 An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients With Depression
Protocol 0600B1-4433-US Sponsor: Wyeth Res.Div. of WyethPharmaceuticals
- 2008 A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 60 mg TID in Subjects with Major Depressive Disorder
Protocol CX157-200 Sponsor: CeNeRx BioPharma, Inc
- 2009 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (10 and 50 mg/day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder
Protocol 3151A1-3362-US Sponsor: Wyeth Pharmaceuticals
- 2009 A Study of Augmentation with LY2216684 for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Protocol H9P-MC-LNDK Sponsor: Eli Lilly
- 2009 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects with Major Depressive Disorder
Protocol NKG111733 Sponsor: GlaxoSmithKline
- 2009 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Posttraumatic Stress Disorder (PTSD)
Protocol NKG 113211 Sponsor: GlaxoSmithKline

2010 A Double-Blind Efficacy and Safety Study of Duloxetine versus Placebo in the Treatment
of Children and Adolescents with Major Depressive Disorder
Protocol F1J-MC-HMCL Sponsor: Eli Lilly and Co.

Revised April, 2010